Yixintang Pharmaceutical Group Co., Ltd. (002727) Stock Recommendation | Score, Valuation, Technicals & Financial Trend

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Comparison

Company

Score

Quality

Valuation

Financial

Technical

Yixintang Pharmaceutical Group Co., Ltd.

Why is Yixintang Pharmaceutical Group Co., Ltd. ?

Poor long term growth as Net Sales has grown by an annual rate of 5.56% and Operating profit at -13.28% over the last 5 years

Positive results in Mar 26

RAW MATERIAL COST(Y) Fallen by -6.01% (YoY)
DEBT-EQUITY RATIO (HY) Lowest at 8.19 %
PRE-TAX PROFIT(Q) Highest at CNY 225.94 MM

With ROE of 3.78%, it has a fair valuation with a 0.59 Price to Book Value

Over the past year, while the stock has generated a return of -33.71%, its profits have risen by 414.2% ; the PEG ratio of the company is 0
At the current price, the company has a high dividend yield of 5.4

Consistent Underperformance against the benchmark over the last 3 years

Along with generating -33.71% returns in the last 1 year, the stock has also underperformed China Shanghai Composite in each of the last 3 annual periods

Real-Time Research Report

Verdict Report

How much should you hold?

Overall Portfolio exposure to Yixintang Pharmaceutical Group Co., Ltd. should be less than 10%
Overall Portfolio exposure to Retailing should be less than 30%

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Retailing)

When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock

Is Yixintang Pharmaceutical Group Co., Ltd. for you?

Medium Risk, Low Return

Absolute

Risk Adjusted

Volatility

Yixintang Pharmaceutical Group Co., Ltd.

-34.6%

-1.53

27.16%

China Shanghai Composite

19.22%

1.46

13.80%

Quality

Management Risk

Growth

Capital Structure

Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor

Value

Sales Growth (5y)

5.56%

EBIT Growth (5y)

-13.28%

EBIT to Interest (avg)

9.22

Debt to EBITDA (avg)

Net Debt is too low

Net Debt to Equity (avg)

0.01

Sales to Capital Employed (avg)

1.61

Tax Ratio

70.33%

Dividend Payout Ratio

87.51%

Pledged Shares

Institutional Holding

ROCE (avg)

12.89%

ROE (avg)

9.80%

Valuation

Valuation Scorecard

Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors

Factor

Value

P/E Ratio

Industry P/E

Price to Book Value

0.59

EV to EBIT

8.45

EV to EBITDA

2.54

EV to Capital Employed

0.56

EV to Sales

0.23

PEG Ratio

0.04

Dividend Yield

5.39%

ROCE (Latest)

6.61%

ROE (Latest)

3.78%

Technicals

Technical key factors

Indicator

Weekly

Monthly

MACD

Bearish

Mildly Bullish

RSI

Bullish

Bearish

Bollinger Bands

Bearish

Moving Averages

Bearish (Daily)

KST

Bearish

Dow Theory

Bearish

OBV

Mildly Bearish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Technical Movement

Analyse All Technical Factors

Financial Trend

Financial Trend Scorecard

Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

16What is working for the Company

RAW MATERIAL COST(Y)

Fallen by -6.01% (YoY

DEBT-EQUITY RATIO (HY)

Lowest at 8.19 %

PRE-TAX PROFIT(Q)

Highest at CNY 225.94 MM

NET PROFIT(Q)

Highest at CNY 175.06 MM

EPS(Q)

Highest at CNY 0.31

-7What is not working for the Company

INTEREST COVERAGE RATIO(Q)

Lowest at 770.77

OPERATING PROFIT MARGIN(Q)

Lowest at 5.03 %

INVENTORY TURNOVER RATIO(HY)

Lowest at 3.01 times

OPERATING PROFIT(Q)

Lowest at CNY 222.85 MM

Here's what is working for Yixintang Pharmaceutical Group Co., Ltd.

Pre-Tax Profit

Highest at CNY 225.94 MM

in the last five periods

MOJO Watch

Near term Pre-Tax Profit trend is positive

Pre-Tax Profit (CNY MM)

Net Profit

Highest at CNY 175.06 MM

in the last five periods

MOJO Watch

Near term Net Profit trend is positive

Net Profit (CNY MM)

EPS

Highest at CNY 0.31

in the last five periods

MOJO Watch

Increasing profitability; company has created higher earnings for shareholders

EPS (CNY)

Debt-Equity Ratio

Lowest at 8.19 %

in the last five Semi-Annual periods

MOJO Watch

The company has been reducing its borrowing as compared to equity capital

Debt-Equity Ratio

Raw Material Cost

Fallen by -6.01% (YoY)

MOJO Watch

The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin

Raw Material Cost as a percentage of Sales

Here's what is not working for Yixintang Pharmaceutical Group Co., Ltd.

Interest Coverage Ratio

Lowest at 770.77 and Fallen

In each period in the last five periods

MOJO Watch

The company's ability to manage interest payments is deteriorating

Operating Profit to Interest

Operating Profit Margin

Lowest at 5.03 % and Fallen

In each period in the last five periods

MOJO Watch

Company's profit margin has deteriorated

Operating Profit to Sales

Operating Profit

Lowest at CNY 222.85 MM

in the last five periods

MOJO Watch

Near term Operating Profit trend is negative

Operating Profit (CNY MM)

Inventory Turnover Ratio

Lowest at 3.01 times

in the last five Semi-Annual periods

MOJO Watch

Company's pace of selling inventory has slowed

Inventory Turnover Ratio